Literature DB >> 26079100

The hypoxic tumor microenvironment: A driving force for breast cancer progression.

Gregg L Semenza1.   

Abstract

Intratumoral hypoxia is a common finding in breast cancer and is associated with a significantly increased risk of metastasis and patient mortality. Hypoxia-inducible factors activate the transcription of a large battery of genes encoding proteins that promote primary tumor vascularization and growth, stromal cell recruitment, extracellular matrix remodeling, premetastatic niche formation, cell motility, local tissue invasion, extravasation at sites of metastasis, and maintenance of the cancer stem cell phenotype that is required to generate secondary tumors. Recent preclinical studies suggest that the combination of cytotoxic chemotherapy with drugs that inhibit hypoxia-inducible factors may improve outcome for women with triple-negative breast cancer. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer Cell Survival, Metastasis, Inflammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L. Semenza.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone metastasis; Lung metastasis; Lymph node metastasis; Mesenchymal stem cells; Microvesicles; Myeloid-derived suppressor cells; Tumor-associated macrophages

Mesh:

Substances:

Year:  2015        PMID: 26079100      PMCID: PMC4678039          DOI: 10.1016/j.bbamcr.2015.05.036

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  105 in total

1.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

2.  Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.

Authors:  Jean-Philippe Dales; Stéphane Garcia; Séverine Meunier-Carpentier; Lucile Andrac-Meyer; Olivier Haddad; Marie-Noölle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Int J Cancer       Date:  2005-09-20       Impact factor: 7.396

3.  Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes.

Authors:  Jung Eun Park; Hon Sen Tan; Arnab Datta; Ruenn Chai Lai; Huoming Zhang; Wei Meng; Sai Kiang Lim; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-02-01       Impact factor: 5.911

4.  Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy.

Authors:  Christelle P El-Haibi; George W Bell; Jiangwen Zhang; Anthony Y Collmann; David Wood; Cally M Scherber; Eva Csizmadia; Odette Mariani; Cuihua Zhu; Antoine Campagne; Mehmet Toner; Sangeeta N Bhatia; Daniel Irimia; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-02       Impact factor: 11.205

5.  Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.

Authors:  Toru Hiraga; Shinae Kizaka-Kondoh; Kiichi Hirota; Masahiro Hiraoka; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

6.  RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease.

Authors:  Antonia Bellizzi; Anita Mangia; Annalisa Chiriatti; Stella Petroni; Michele Quaranta; Francesco Schittulli; Andrea Malfettone; Rosa Angela Cardone; Angelo Paradiso; Stephan Joel Reshkin
Journal:  Int J Mol Med       Date:  2008-07       Impact factor: 4.101

7.  HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs.

Authors:  H Zhang; C C L Wong; H Wei; D M Gilkes; P Korangath; P Chaturvedi; L Schito; J Chen; B Krishnamachary; P T Winnard; V Raman; L Zhen; W A Mitzner; S Sukumar; G L Semenza
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

8.  Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

Authors:  Tiansuo Zhao; He Ren; Li Jia; Jing Chen; Wen Xin; Fan Yan; Jing Li; Xiuchao Wang; Song Gao; Dong Qian; Chongbiao Huang; Jihui Hao
Journal:  Oncotarget       Date:  2015-02-10

9.  Collagen prolyl hydroxylases are essential for breast cancer metastasis.

Authors:  Daniele M Gilkes; Pallavi Chaturvedi; Saumendra Bajpai; Carmen C Wong; Hong Wei; Stephen Pitcairn; Maimon E Hubbi; Denis Wirtz; Gregg L Semenza
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

10.  Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.

Authors:  M Aga; G L Bentz; S Raffa; M R Torrisi; S Kondo; N Wakisaka; T Yoshizaki; J S Pagano; J Shackelford
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

View more
  168 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  Hypoxia-induced secretion of IL-10 from adipose-derived mesenchymal stem cell promotes growth and cancer stem cell properties of Burkitt lymphoma.

Authors:  Lihua Xu; Xu Wang; Jiani Wang; Dan Liu; Yaya Wang; Zhenqian Huang; Huo Tan
Journal:  Tumour Biol       Date:  2015-12-23

3.  Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation.

Authors:  Annegret Kathagen-Buhmann; Alexander Schulte; Jonathan Weller; Mareike Holz; Christel Herold-Mende; Rainer Glass; Katrin Lamszus
Journal:  Neuro Oncol       Date:  2016-02-24       Impact factor: 12.300

4.  Extracellular volatilomic alterations induced by hypoxia in breast cancer cells.

Authors:  Ravindra Taware; Khushman Taunk; Totakura V S Kumar; Jorge A M Pereira; José S Câmara; H A Nagarajaram; Gopal C Kundu; Srikanth Rapole
Journal:  Metabolomics       Date:  2020-01-24       Impact factor: 4.290

5.  Catalase-Functionalized Iron Oxide Nanoparticles Reverse Hypoxia-Induced Chemotherapeutic Resistance.

Authors:  Tin-Yo Yen; Zachary R Stephen; Guanyou Lin; Qingxin Mu; Mike Jeon; Stela Untoro; Parker Welsh; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2019-09-26       Impact factor: 9.933

6.  Abnormal Golgi pH Homeostasis in Cancer Cells Impairs Apical Targeting of Carcinoembryonic Antigen by Inhibiting Its Glycosyl-Phosphatidylinositol Anchor-Mediated Association with Lipid Rafts.

Authors:  Nina Kokkonen; Elham Khosrowabadi; Antti Hassinen; Deborah Harrus; Tuomo Glumoff; Thomas Kietzmann; Sakari Kellokumpu
Journal:  Antioxid Redox Signal       Date:  2018-02-12       Impact factor: 8.401

7.  Run for your life: an integrated virtual tissue platform for incorporating exercise oncology into immunotherapy.

Authors:  Josua Aponte Serrano; Amit Hagar
Journal:  Cancer Immunol Immunother       Date:  2021-01-08       Impact factor: 6.968

8.  Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells.

Authors:  H Marzook; S Deivendran; B George; G Reshmi; T R Santhoshkumar; R Kumar; M R Pillai
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

9.  CoCl2 increases the expression of hypoxic markers HIF-1α, VEGF and CXCR4 in breast cancer MCF-7 cells.

Authors:  Qing Li; Rong Ma; Mei Zhang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

10.  Reprogramming of m6A epitranscriptome is crucial for shaping of transcriptome and proteome in response to hypoxia.

Authors:  Yan-Jie Wang; Bing Yang; Qiao Lai; Jun-Fang Shi; Jiang-Yun Peng; Yin Zhang; Kai-Shun Hu; Ya-Qing Li; Jing-Wen Peng; Zhi-Zhi Yang; Yao-Ting Li; Yue Pan; H Phillip Koeffler; Jian-You Liao; Dong Yin
Journal:  RNA Biol       Date:  2020-08-18       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.